Based on the favorable safety profiles of PRAME as a target antigen and MDG1011 in vitro and in vivo, this TCR-T therapy approach merits further investigation as a potential ACT to fill the unmet medical need for patients suffering from myeloid malignancies. The gene discussed is PRAME; the disease is myeloid neoplasm.